- Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test<figure><div><img src="https://imgproxy.divecdn.com/-VJqYiEfcoBd7qksclMxxfyJncEOUGAsA4I3KzG8Vpc/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzM4Mzc0MDE5LmpwZ…BioPharma Dive · 1mo ago↗ source
- Ethyreal starts up with $101M and takes aim at a pair of immune diseases<figure><div><img src="https://imgproxy.divecdn.com/egbyTu8esim-VjYj5FTvMQUlBrndW-s35OSn02s-EoY/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMzk4NTE5MTYzLmpwZ…BioPharma Dive · 1mo ago↗ source
- Sanofi stops immune drug trial in latest research setback<p>The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential blockbuster.</p>